| Published Application/Species/Sample/Dilution | Reference |
|---|
- flow cytometry; human; loading ...; fig s4b
| Solis N, Swidergall M, Bruno V, Gaffen S, Filler S. The Aryl Hydrocarbon Receptor Governs Epithelial Cell Invasion during Oropharyngeal Candidiasis. MBio. 2017;8: pubmed publisher |
- ChIP-Seq; mouse; fig s3a
- chromatin immunoprecipitation; mouse; fig s3b
- ChIP-Seq; human; loading ...; fig s3c
- chromatin immunoprecipitation; human; fig s3e
| Seberg H, Van Otterloo E, Loftus S, Liu H, Bonde G, Sompallae R, et al. TFAP2 paralogs regulate melanocyte differentiation in parallel with MITF. PLoS Genet. 2017;13:e1006636 pubmed publisher |
- western blot; human; 1:1000; fig 2
| Jiang Q, Chen S, Hu C, Huang P, Shen H, Zhao W. Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease. Mol Med Rep. 2016;14:2614-24 pubmed publisher |
- western blot; mouse; 1:500; fig 2
| Yang Z, Jiang Q, Chen S, Hu C, Shen H, Huang P, et al. Differential changes in Neuregulin-1 signaling in major brain regions in a lipopolysaccharide-induced neuroinflammation mouse model. Mol Med Rep. 2016;14:790-6 pubmed publisher |
- immunohistochemistry - paraffin section; human; tbl 3
| Hagrass H, Sharaf S, Pasha H, Tantawy E, Mohamed R, Kassem R. Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer. 2015;6:281-7 pubmed |
| Jung S, Ohk J, Jeong D, Li C, Lee S, Duan J, et al. Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells. Int J Oncol. 2014;45:189-96 pubmed publisher |
| Iyer P, Shrikhande S, Ranjan M, Joshi A, Gardi N, Prasad R, et al. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer. Int J Cancer. 2019;144:2008-2019 pubmed publisher |
| Tang T, Zhang D. Study on extracellular matrix metalloproteinase inducer and human epidermal growth factor receptor-2 protein expression in papillary thyroid carcinoma using a quantum dot-based immunofluorescence technique. Exp Ther Med. 2015;9:1331-1335 pubmed |
| Panis C, Pizzatti L, Corrêa S, Binato R, Lemos G, Herrera A, et al. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Lett. 2015;357:186-95 pubmed publisher |
| Färkkilä A, Andersson N, Butzow R, Leminen A, Heikinheimo M, Anttonen M, et al. HER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study. Cancer Med. 2014;3:526-36 pubmed publisher |
| Kang J, Poovassery J, Bansal P, You S, Manjarres I, Ober R, et al. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs. 2014;6:340-53 pubmed publisher |
| Zhu Z, Wang J, Sun Z, Sun X, Wang Z, Xu H. Flotillin2 expression correlates with HER2 levels and poor prognosis in gastric cancer. PLoS ONE. 2013;8:e62365 pubmed publisher |
| Hung S, Chiu C, Chen T, Chu C, Huang C, Shyur L, et al. Recombinant viral protein VP1 suppresses HER-2 expression and migration/metastasis of breast cancer. Breast Cancer Res Treat. 2012;136:89-105 pubmed publisher |
| Ward T, Iorns E, Liu X, Hoe N, Kim P, Singh S, et al. Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5. Oncogene. 2013;32:2463-74 pubmed publisher |
| Yuan H, Upadhyay G, Lu J, Kopelovich L, Glazer R. The chemopreventive effect of mifepristone on mammary tumorigenesis is associated with an anti-invasive and anti-inflammatory gene signature. Cancer Prev Res (Phila). 2012;5:754-64 pubmed publisher |
| Fessler S, Wotkowicz M, Mahanta S, Bamdad C. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat. 2009;118:113-24 pubmed publisher |
